Excellent Response to Full-Dose 177Lu-PSMA-617 RLT in Metastatic Castration-Resistant Prostate Cancer With Transplant Kidney

Mahdi, Raza Abbas; Aggarwal, Piyush; Kumar, Suraj; Sood, Ashwani; Paul, Davinder; Mittal, Bhagwant Rai

doi:10.1097/rlu.0000000000004781

Cited by 1 publication

(1 citation statement)

References 9 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lutetium-177 targeted therapy, highlighted in both a prospective study and a case report, underscores the importance of dose reduction in minimizing the nephrotoxicity risk. These studies show the therapy's effectiveness while maintaining an acceptable adverse event profile [113,114]. There are several cases in the literature describing the possibility of using drugs in the treatment of PCa during immunosuppression caused by liver or renal transplantation [115,116].…”

Section: Metastatic Prostate Cancer In Transplant Receiversmentioning

confidence: 99%

Prostate Cancer in Transplant Receivers—A Narrative Review on Oncological Outcomes

Hanusz,

Domański,

Strojec

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Prostate cancer (PCa) is a low tumor mutational burden (TMB) cancer with a poor response to immunotherapy. Nonetheless, immunotherapy can be useful, especially in metastatic castration-resistant PCa (mCRPC). Increased cytotoxic T lymphocytes (CTLs) density is correlated with a shorter overall survival (OS), an early biochemical relapse, and a generally poor PCa prognosis. An increased number of CCR4+ regulatory T cells (CCR4 + Tregs) relates to a higher Gleason score or earlier progression. The same therapeutic options are available for renal transplant recipients (RTRs) as for the population, with a comparable functional and oncological outcome. Radical retropubic prostatectomy (RRP) is the most common method of radical treatment in RTRs. Brachytherapy and robot-assisted radical prostatectomy (RARP) seem to be promising therapies. Further studies are needed to assess the need for prostatectomy in low-risk patients before transplantation. The rate of adverse pathological features in RTRs does not seem to differ from those observed in the non-transplant population and the achieved cancer control seems comparable. The association between PCa and transplantation is not entirely clear. Some researchers indicate a possible association between a more frequent occurrence of PCa and a worse prognosis in advanced or metastatic PCa. However, others claim that the risk and survival prognosis is comparable to the non-transplant population.

show abstract

Section: Metastatic Prostate Cancer In Transplant Receiversmentioning

confidence: 99%